Abstract. The aim of the present study was to investigate the potential therapeutic effects of molecular hydrogen on type 2 diabetes mellitus (T2DM) in rats. Following maintenance on a high-fat diet for 4 weeks, a T2DM model was established using an injection of 30 mg/kg streptozotocin via the caudal vein into Sprague-Dawley rats. On day 0 and Day 80, the blood samples were obtained from each rat for the measurement of biochemical indicators including blood lipids, fasting blood glucose, hepatic glycogen, fasting serum insulin, insulin sensitivity index, insulin resistance index, serum superoxide dismutase (SOD) and serum malondialdehyde (MDA) using an automatic biochemical analyzer. The kidneys and pancreas tissues were harvested for HE staining and Western blot assay of toll-like receptor 4 (TLR4), myeloid differentiation primary response 88 (MyD88), phosphorylated (p)-p65, p65, p-IκB and IκB. The results showed that in rats with T2DM, molecular hydrogen treatment decreased fasting blood glucose levels, increased hepatic glycogen synthesis and improved insulin sensitivity. Treatment with molecular hydrogen also increased the production of SOD whilst decreasing the production of MDA. In addition, molecular hydrogen alleviated the pathological changes exhibited by pancreatic islets and kidney during T2DM. Mechanistically, molecular hydrogen decreased TLR4 and MyD88 expression levels whilst also decreasing p65 and NF-κB inhibitor phosphorylation. In conclusion, molecular hydrogen exerted therapeutic effects against T2DM by improving hyperglycemia and inhibiting oxidative stress through mechanisms that are associated with the TLR4/MyD88/NF-κB signaling pathway.

Introduction

Diabetes mellitus (DM), characterized by chronic hyperglycemia, is a multi-factorial metabolic disorder that is also gaining recognition as a chronic inflammatory disease (1). Physiological reactive oxygen species (ROS) is essential for the maintenance and regulation of a number of important physiological processes, including cell proliferation, apoptosis and Ca²⁺ signaling (2). However, excessive ROS production can induce damage to proteins, DNA and lipids caused by oxidative stress (3). Hyperglycemia increases the intracellular NADH/NAD⁺ ratio, increasing the risk of electron leakage from NADH or FADH₂ of the electron transport chain, in turn resulting in increased ROS production (4). Additionally, hyperglycemic states can also decrease the expression and activity of enzymes that eliminate ROS, further aggravating oxidative stress (5). Previous studies have demonstrated that excessive ROS accumulation in the mitochondria induced by hyperglycemia can cause damage to the mitochondrial inner membrane. Firstly, ROS can increase inner membrane fluidity and permeability, adversely altering mitochondrial osmotic pressure, causing the organelle to swell; secondly, ROS can destroy the mitochondrial membrane potential and in turn reduce ATP synthesis (6,7). Downstream, this can promote the efflux of apoptotic factors from the mitochondrial matrix and activate apoptotic pathways in the cytosol, resulting in islet cell and renal podocyte apoptosis (8,9).

In recent years, it has become evident that Hydrogen (H₂) is an effective treatment for various disease models such as myocardial ischemia-reperfusion injury, COPD, and lipid metabolism disorders (10-12). Although previous studies in rats have revealed that hydrogen production exhibited beneficial therapeutic effects on early islet cells, the mechanism underlying this protection remains poorly understood (13,14). Therefore, in the present study, using rat models with type 2 DM (T2DM) induced by high-fat feeding combined with low-dose streptozotocin (STZ) injection, the potential therapeutic effects of H₂ in T2DM were evaluated. Particular emphasis was placed on glucose metabolism, insulin resistance, lipid metabolism, oxidative stress and histological morphology along with the associated molecular mechanisms. The present study aimed to provide further understanding for the clinical application of H₂ in the treatment of T2DM.
Materials and methods

Preparation and grouping of diabetic rat models. The present study was approved by the animal ethics committee of Weifang Peoples Hospital (approval no. WFPH2016011K; Weifang, China). A total of 50 Specific-pathogen-free Sprague Dawley rats (2 months old; male:female=1:1), weighing 200±20 g, were purchased from Weifang People's Hospital (license no. WFPH2016011K). The animals were maintained at 22-25°C and a relative humidity of 40-70% with a 12-h light/dark cycle and provided ad libitum access to food and drinking water. Following normal feed for 3 days, rats were randomized into the following two groups: i) High fat (n=40); and ii) normal (n=10; male:female, 1:1). The high-fat feed composed of 59% common feed, 10% lard, 10% yolk powder, 20% sucrose and 1% cholesterol, which was provided by Weifang People's Hospital. After 4 weeks of this high-fat diet, animals in the T2DM model group received a tail vein injection of 30 mg/kg STZ (Sigma-Aldrich; Merck KGaA), following which fasting blood glucose concentrations of the rats were measured 1 week later. Rats with fasting blood glucose concentrations <16.7 mmol/l received a second dose of STZ (30 mg/kg) immediately after glucose measurements through tail veins prior to another round of fasting blood glucose measurements 1 week later. Rats with fasting blood glucose concentrations >16.7 mmol/l were considered to be diabetic (15). Diabetic model rats were subsequently randomized into three groups (n=10 in each group; male:female, 1:1): i) H₂; ii) positive control (300 mg/kg metformin via intragastric injection; Sino-American Shanghai Squibb Pharmaceutical Co., Ltd.); and iii) model (equivalent volume of physiological saline). During the H₂ administration period, diabetic rats in the H₂ group were provided with 500 µl saturated hydrogen saline by intragastric injection. In addition, a high-fat diet control group (n=10; male:female, 1:1) was set, where the animals were fed on a high-fat diet for 4 weeks followed by the intragastric delivery of an equivalent volume of physiological saline parallel to the H₂ administration; during the H₂ administration period, rats in the high-fat diet control group received an equivalent volume of physiological saline. Rats in the normal group (n=10) were fed with common feed for 4 weeks, following which they were injected with an equal volume of physiological saline via the tail vein; during the H₂ administration period, rats in the normal group received an equivalent volume of physiological saline. All rats were treated with either H₂, metformin or physiological saline daily for 80 consecutive days. The body weights of all animals were recorded after every 2 weeks. Saturated hydrogen saline was prepared in the Center of Modern Analysis and Detection of Xi'an Jiaotong University. Molecular H₂ was dissolved in normal saline at high pressure (13.5 Mpa) to form a saturated solution, which was subsequently stored in aluminum packaging to maintain the H₂ concentration at >0.6 mmol/l.

Preparation of samples. On day 0 of treatment, following 12 h fasting, blood samples (0.5-1 ml) were obtained from the tail veins of rats from each group under anesthesia with 4% diethyl ether. Following centrifugation at 4°C and 1,800 x g for 15 min, the supernatants were collected for the measurement of biochemical indicators. On day 80, after 8 h fasting, the rats were euthanized following an intravenous injection of 100 mg/kg sodium pentobarbital, following which 1 ml blood samples were taken from the hepatic portal veins of rats in each group. Following centrifugation at 4°C and 1,800 x g for 15 min, the supernatants were collected for the measurement of biochemical indicators. Subsequent to euthanasia, the kidneys and pancreas tissues were harvested from the rats in each group, rinsed with saline and dried using filter paper. The tissues were then fixed with 10% formaldehyde at 4°C for 24 h. After gradient ethanol elution, xylene transparentizing and paraffin embedding, tissues were cut into 2-5 µm sections. The sections were mounted on glass slides and baked for 45 min at 80°C and treated with xylene I and xylene II (Tiangen Biotech Co. Ltd.) for 20 min. Samples were then incubated at room temperature with 95, 85 and 75% alcohol (3 min for each concentration). Sections were stained with haematoxylin for 60 sec and eosin for 30 sec (Sigma-Aldrich; Merck KGaA) at room temperature. Sections were sealed using neutral gum and observed under inverted microscope (Model, IX70; Olympus Corporation).

Measurement of biochemical indicators. To evaluate the efficacy of H₂ for the treatment of T2DM, fasting blood glucose, hepatic glycogen, fasting serum insulin, insulin sensitivity index, insulin resistance index, serum superoxide dismutase (SOD) and serum malondialdehyde (MDA) were measured in samples collected from rats in each group. Serum glucose was assayed using glucose oxidase-peroxidase method, whereas hepatic glycogen was measured using the anthraquinone method. Serum insulin was assayed by double antibody sandwich ELISA, serum SOD was measured using the WST-1 method, which is based on the cleavage of the tetrazolium salt WST-1 to formazan by SOD. Serum MDA was measured using the 2-thiobarbituric acid (TBA) method, which is based on the colored substances produced by interactions between MDA and TBA. All assays were performed according to the protocols of the respective manufacturers. Glucose assay kits (cat. no. F006-1-1), SOD kits (cat. no. A001-3-2), MDA assay kits (cat. no. A003-1-2), hepatic/muscle glycogen kits (cat. no. A043-1-1) were purchased from Nanjing Jiancheng Bioengineering Institute, whilst the rat insulin ELISA kits (cat. no. 10-1250-01) were purchased from Merckodia AB.

Measurement of blood lipids. An automatic biochemical analyzer (AU680; Beckman Coulter, Inc.) was used to measure triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c) and low-density lipoprotein cholesterol (LDL-c) levels in the blood samples collected from each rat. Each condition was examined in triplicate in parallel and were subsequently averaged. TC, TG, HDL-c and LDL-c kits were purchased from Roche Diagnostics. Test procedures for each item were performed in strict accordance with the manufacturer's protocols.

Calculation of insulin resistance. Insulin resistance was calculated using values obtained from fasting blood glucose and fasting insulin measurements in accordance with the following formula: Insulin resistance index (IRI)=(fasting blood glucose x fasting insulin)/22.5 (16).
Western blotting. Pancreatic tissues (1 mg) were lysed using RIPA buffer (Beijing Dingguo Changsheng Biotechnology Co., Ltd.) supplemented with proteinase inhibitor for 30 min on ice and subsequently centrifuged at 12,000 x g at 4°C for 15 min. Protein concentration was quantified using bicinchoninic acid assay protein quantitative kit (Beyotime Institute of Biotechnology). Protein (50 µg) was separated by 10% SDS-PAGE prior to transferal onto PVDF membranes. The membranes were then blocked using 5% skim milk at room temperature for 1 h. Primary antibodies (all obtained from Abcam) against toll-like receptor 4 (TLR4; 1:400; cat. no. ab13556), myeloid differentiation primary response 88 (MyD88; 1:400; cat. no. ab2064), phosphorylated (p)-p65 (1:500; cat. no. ab133462), IκB (1:1,000; cat. no. ab12134) and β-actin (1:2,000; cat. no. ab8226) were subsequently used to incubate the membranes overnight at 4°C. The membranes were then incubated with horseradish peroxidase-conjugated goat anti-rabbit antibodies (cat. no. BA1055; 1:2,000; Boster Biological Technology) at 37°C for 1 h. ECL (Beijing Dingguo Changsheng Biotechnology Co., Ltd.) reagent was used to visualize the protein bands. Quantity One Software (version 4.6.9; Bio-Rad Laboratories, Inc.) was used to perform quantitative densitometric analysis (17) where β-actin was used as loading control.

Statistical analysis. Experimental data in each group were presented as mean ± standard deviation; sample means among groups were compared using one-way ANOVA followed by Tukey’s test for all data using SPSS 18.0 software (SPSS Inc.). P<0.05 was considered to indicate a statistically significant difference.

Results

H₂ can effectively restore blood glucose levels following T2DM induction. The effect of H₂ on fasting blood glucose levels in rats following the induction of T2DM is shown in Fig. 1A. The mean fasting blood glucose levels were significantly increased in the model group on both days 0 and 80 when compared with the HF control. On day 80, fasting blood glucose levels in the H₂ group were significantly decreased

Figure 1. H₂ can effectively restore blood glucose levels and alleviate insulin resistance 80 days following T2DM induction. (A) The effect of H₂ on fasting blood glucose levels. (B) The effect of H₂ on the hepatic glycogen content. (C) The effect of H₂ on fasting serum insulin levels. (D) The effect of H₂ on insulin sensitivity. *P<0.05 and **P<0.01 vs. HF control; †P<0.05 and ††P<0.01 vs. Model. HF, high-fat feed; T2DM, type 2 diabetes mellitus.
compared with the model group. On the same day, hepatic glycogen content in the H₂ group was significantly increased compared with that in the model group (Fig. 1B). The effect of H₂ on fasting serum insulin levels in rats following the induction of T2DM is shown in Fig. 1C. Compared with the model group, no significant differences were observed.
in the fasting serum insulin levels on days 0 or 80 in the H₂ group. The effect of H₂ on insulin sensitivity in rats following the induction of T2DM is presented in Fig. 1D. On day 80, compared with the normal group, IRI was significantly increased in the model group, whilst the IRI was significantly decreased in H₂ group compared with the model group.

**H₂ can effectively restore blood lipid levels following T2DM.** The average weights of the rats in the model group were significantly decreased compared with the HF control group from week 6 onwards, whilst the average weights of the rats in the H₂ group were significantly increased compared with those in the model group (Fig. 2A and B). The serum levels of TG, TC and LDL-c in the model group were significantly increased compared with those in the HF control group, whereas the serum levels of HDL-c in the model group were significantly decreased compared with those in the HF control group (Fig. 2C). In the H₂ group, the TG, TC and LDL-c levels were significantly decreased, whereas the levels of HDL-c were significantly increased compared with those in the model group (Fig. 2C). The corresponding levels of TG, TC and HDL-c in the positive control metformin group exhibited no protective effects, suggesting that H₂ was more effective in restoring the levels of blood lipids following T2DM induction.

**H₂ can alleviate oxidative stress and pathological morphology induced by T2DM.** The effect of H₂ on SOD levels of rats with T2DM was shown in Fig. 3A. Compared with the HF control group, SOD levels in the model group were significantly decreased on day 80, whereas serum SOD content in the H₂ group was significantly increased compared with the model group. Additionally, serum MDA concentrations were significantly decreased in the H₂ group on day 80 compared with those from the model group, which was in turn significantly increased compared with the HF control group (Fig. 3B).

H&E staining results of pancreatic islets collected on day 80 are shown in Fig. 3C. In the normal group, the islets were morphologically complete with clearly visible boundaries between islets and exocrine glands, where the number of cells in the islets was large and the cells were densely and uniformly arranged. In the model group, the islets were irregular in morphology, where the boundaries between the islets and exocrine glands became ambiguous and the quantity of cytoplasm in islet cells was decreased; some islet cells also exhibited vacuolar degeneration in the cytoplasm. In the H₂ group, the islets were complete in morphology with clear boundaries between islets and exocrine glands, where the quantity of cytoplasm in islet cells was markedly increased with decreased vacuolar degeneration compared with those in the model group. H&E staining results of the glomeruli are shown in Fig. 3D. The glomeruli of the rats in
the normal group were complete in morphology with clear contours and regular arrangement, where no abnormalities were observed in the tubules. In the model group, capsular spaces were narrowed with tubular structures exhibiting disorder. In the H\textsubscript{2} group, the glomeruli were morphologically complete with regularly arranged structures, where the tubules clearly visible, comparable with those observed in the control group.

\textbf{Discussion}

In the present study, to mimic the progression of T2DM in humans, rat models of T2DM induced by a high-fat diet followed by low-dose STZ injection were generated. Compared with the rats with spontaneous diabetes, model animals such as those used in the present study are readily available, are more cost effective and therefore have been used for evaluating drug efficacy for T2DM (19,20). In the present study, compared with the HF control group, the model group exhibited significantly increased fasting blood glucose levels and insulin resistance, though no significant difference was observed in fasting serum insulin levels. In addition, compared with those in the HF control group, the levels of TG, TC and LDL-c were significantly increased, whilst the levels of HDL-c were significantly decreased in the model group. Serum SOD and MDA concentrations were significantly decreased and increased on day 80.

\textbf{H\textsubscript{2} can inhibit TLR4/MyD88/NF-\kappa B signaling.} The TLR4/NF-\kappa B signaling pathway has been previously demonstrated to serve an important role in STZ-induced diabetic rats fed on a high-fat diet (18). Western blot analysis revealed that \textit{H\textsubscript{2}} treatment significantly inhibited the expression levels of TLR4 and MyD88, in addition to significantly decreasing p65 and I\kappa B phosphorylation in pancreatic tissues isolated on day 80 compared with the model group (Fig. 4).
in the model group compared with those in the HF control group, respectively. Therefore, these results suggest that a high-fat + high-sugar diet followed by low-dose STZ injection can induce the symptoms of hyperglycemia, hyperlipidemia and oxidative stress in rats, making it a suitable animal model for investigating drug efficacy for anti-diabetic treatments.

In the present study, changes in glucose metabolism, insulin resistance, lipid metabolism and oxidative stress in diabetic rats were observed following intragastric H₂ administration. Typically, blood glucose is used for oxidative phosphorylation in most tissues, converted into hepatic or muscle glycogen for storage, converted to other sugars and derivatives or non-sugar substances for use in other pathways and excreted by urine if blood glucose concentration becomes too high (21). In the present study, glycogen levels in the blood isolated from the hepatic portal vein was higher in the H₂ group, suggesting that H₂ can promote the synthesis of hepatic glycogen whilst improving the utilization of glucose in the liver and lower fasting blood sugar concentration. Insulin resistance is a core characteristic in T2DM pathophysiology that is closely associated with lipid metabolism disturbance, damage to islet β-cells and finally islet failure (22). Therefore, it is of utmost importance to delay T2DM progression by improving insulin resistance. Data from the present study suggested that H₂ treatment did not affect insulin concentration whilst improving insulin sensitivity in diabetic rats, alleviating the symptoms of insulin resistance.

Previous studies have revealed aberrant lipid metabolism in patients with T2DM, where high blood glucose levels, insulin resistance and hyperinsulinemia all contribute to the dysfunction of lipoprotein metabolism in the body (23,24). The present study revealed that the levels of TG, TC and LDL-c in the model group were significantly increased compared with those in the HF control group, whilst the levels of HDL-c in the model group were significantly decreased compared with those in the HF control group. H₂, but not the positive control metformin, exerted protective effects on blood lipids during T2DM induction, suggesting that H₂ can reverse the dysfunction in blood lipid metabolism during T2DM pathogenesis.

Oxidative stress is an important cause of diabetes and its associated complications (25). Metabolism under hyperglycemic conditions leads to the production of excessive quantities of superoxides and the inactivation of antioxidants in the body (26). Therefore, ROS oxidative stress serves an important role in the pathogenesis of diabetes (27). The effects of H₂ on oxidative stress have been previously reported (28,29). The present study demonstrated that H₂ can increase SOD activity whilst decreasing serum MDA content.

TLR4 and one of its endogenous ligands, MyD88, are frequently upregulated in glomeruli of type 1 (STZ-induced) and type 2 (A-ZIP/F-1 lipoatrophic) diabetic mice (30). Activation of TLR4/MyD88 signaling was also previously revealed in an animal model of diabetic glomerular injury accompanied with hyperlipidemia (31). NF-κB is a key transcription factor that initiates immune responses and activates the expression of inflammatory cytokines during oxidative stress downstream of TLR4/MyD8 signaling (32). At resting state, NF-κB exists in the cytoplasm as an inactive NF-κB/IκBα complex. Following activation, IκBα is phosphorylated and subsequently degraded. Following the dissociation of NF-κB and IκBα, NF-κB translocate into the nucleus and activate the transcription of genes associated with inflammation, including nitric oxide, tumor necrosis factor-α, interleukin (IL)-1β and IL-6 (33). The present study suggested that H₂ can effectively suppress the activation of TLR4/MyD88/NF-κB during T2DM.

In conclusion, H₂ is effective for treating T2DM by alleviating hyperglycemia, hyperlipidemia and antioxidant capacity by suppressing TLR4/MyD88/NF-κB signaling. However, further in vivo and in vitro experiments are required to verify the effects of H₂ on sugar and lipid metabolism and NF-κB/IκB signaling.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Weifang Science and Technology Development Plan (grant no. 201202153).

Availability of data and materials

All data generated or analyzed during the present study are included in this published article.

Authors' contributions

YM and QHM performed the experiments. XH performed statistical analysis. HYL designed the current study. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The present study was approved by the animal ethics committee of Weifang Peoples Hospital (approval no. WFPH2016011K; Weifang, China).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


